24 studies found for:    Recurrent GBM | Immunotherapy
Show Display Options
Rank Status Study
1 Active, not recruiting Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
Condition: Recurrent Central Nervous System Neoplasm
Intervention: Biological: BTSC mRNA-loaded DCs
2 Recruiting DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Single intratumoral injection of DNX-2401;   Drug: interferon gamma
3 Recruiting Cellular Immunotherapy Study for Brain Cancer
Conditions: Gliomas;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Mixed Glioma;   Glioblastoma Multiforme;   Malignant Meningioma
Intervention: Drug: alloreactive CTL
4 Completed Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Conditions: Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Brain Stem Glioma;   Ependymoblastoma;   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Grade III Meningioma;   Meningeal Hemangiopericytoma;   Mixed Glioma;   Pineal Gland Astrocytoma;   Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
5 Recruiting Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioblastoma Multiforme;   Glioma;   Astrocytoma;   Brain Tumor
Interventions: Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy;   Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
6 Recruiting A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Condition: Recurrent Glioblastoma
Intervention: Biological: ICT-121 DC vaccine
7 Recruiting Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Conditions: Adult Brain Glioblastoma;   Glioblastoma Multiforme
Interventions: Biological: SL-701; Imiquimod Cream 5%; Leukine 150 micrograms;   Drug: Imiquimod Cream 5%;   Drug: Leukine 150 micrograms
8 Completed A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Vorinostat;   Drug: Bevacizumab;   Drug: Irinotecan
9 Unknown  Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
Conditions: Grade IV Glioma;   Grade IV Astrocytoma;   Glioblastoma Multiforme
Intervention: Biological: TVI-Brain-1
10 Completed Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: therapeutic autologous lymphocytes;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
11 Completed Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Conditions: Glioma;   High Grade Astrocytoma;   Glioblastoma Multiforme
Intervention: Biological: Cancer vaccine plus immune adjuvant, plus activated white blood cells
12 Terminated Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride;   Drug: isotretinoin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
13 Completed Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors
Condition: Glioblastoma
Intervention: Drug: TransMID
14 Not yet recruiting Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Pineal Gland Astrocytoma;   Recurrent Adult Brain Tumor
Interventions: Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
15 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
16 Completed Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
Condition: Glioblastoma
Interventions: Biological: Dendritic Cell Immunotherapy;   Biological: Dendritic Cell Vaccine
17 Active, not recruiting Proteome-based Personalized Immunotherapy of Glioblastoma
Condition: Glioblastoma
Interventions: Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes;   Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
18 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis
19 Recruiting A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Conditions: Malignant Glioma;   Recurrent Ependymoma
Interventions: Biological: AdV-tk;   Drug: valacyclovir;   Radiation: Radiation
20 Active, not recruiting Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Malignant Neoplasms of Brain
Interventions: Biological: tetanus toxoid;   Biological: therapeutic autologous dendritic cells;   Biological: therapeutic autologous lymphocytes

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years